Compugen Ltd at JMP Securities Life Sciences Conference Transcript
It's second day of the JMP Securities Life Sciences Conference. The first presenting company is Compugen, drug discovery and development company that's focused on cancer immunotherapeutic, a specific focus on the DNAM axis. And these guys have, what I think is the leading molecule targeting PVRIG. Here speaking for the company is Eran Ophir, the Senior Vice President of Research & Drug Discovery. Welcome, Eran.
Hi. Thank you. So, good morning and good afternoon, everyone. And thank you JMP Securities for inviting us to present at their Life Science Conference today. So as mentioned, I am Eran Ophir. I am the Senior Vice President of Research and Drug Discovery. I'm delighted to present in behalf of Compugen today.
So who is Compugen? So Compugen is a clinical-stage company in the field of cancer immunotherapy, but also a pioneer in computational targeted identification. So what we do? Use the computational capabilities, and we do it for quite a while now for identifying new
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |